Fairytale ending? Mythic flags new approach to improving ADC performance

December 2021 saw the launch of a new US based biotech, Mythic Therapeutics, with an oversubscribed Series B financing round of US$103m.

Related Keywords

China ,Chinese ,Brian Fiske , ,Global Investors ,Venrock Healthcare Capital Partners ,Foresite Capital ,Perceptive Advisors ,Highside Capital ,Bio Developments ,Pipelines ,Antibody Drug Conjugates ,Lung Cancer ,Payload ,Drinker ,